Post by
Noteable on Jan 11, 2023 12:49pm
Pfizer Covid-19 partner BioNTech growing oncology pipeline
January 11, 2023 - BioNTech is diverting significant resources from its Covid-19 program towards its growing oncology pipeline consisting of cancer therapeutics and cell therapies. The company has 19 oncology programs across 22 clinical trials, including two bispecific antibodies being developed with Roche/Genentech. (2016 announcement)
ONCY's pelareorep has demonstrated that it is significantly synergistic with bispecific antibodies, as posted here in the past.
https://www.fiercebiotech.com/biotech/jpm23-biontech-not-giving-fighting-symptomatic-covid-oncology-ambitions-spread
https://investors.biontech.de/news-releases/news-release-details/biontech-enter-worldwide-strategic-collaboration-genentech
Comment by
Noteable on Jan 11, 2023 1:18pm
Both Pfizer and BioNTech are pubically recognizing the need to divert their internal resources towards the expansion of their growing oncology programs.